LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. At the end of this educational activity, participants should be able to:
2. To learn about Multiple Myeloma outcome data in Kenya and sub-Saharan Africa (SSA)
3. To discuss diagnostics, staging, and evaluation of a multiple myeloma patient
4. To understand the optimal therapies, trends, research, and strategies designed to improve the quality of care in multiple myeloma including discussion on the role of Pharmacovigilance.
5. To understand the role of the multidisciplinary team in multiple Myeloma management
6. To understand the role of Palliative and supportive care in multiple Myeloma management
7. Evaluate tools and resources for the management of multiple myeloma that can be used to achieve effective cancer care delivery and improve the patient experience in SSA
8. To discuss clinical cases between faculty and participants
9. To share experiences on How to set-up a Multiple Myeloma care program in SSA

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

LECTURES/COURSEWORK

Orientation to the course 

1. Multiple Myeloma Data in Kenya and SSA (Chite). 
2. Plasma Dyscrasias, Evaluation, Diagnosis and Staging of Multiple Myeloma 
3. The Role of Pathology in Multiple Myeloma 
4. Risk stratification, treatment of Multiple Myeloma & targeted therapies 
5. Classification of Anti-neoplastic agents used in the treatment of Multiple Myeloma 
6. Pharmacovigilance in the care of Multiple Myeloma patients 
7. Role of stem-cell transplant in Multiple Myeloma 
8. The Role of Radiotherapy in Multiple Myeloma Management 
9. Palliative and supportive care in multiple Myeloma management 
10. Multiple Myeloma Clinical Cases by Faculty and Participants 
11. How to set-up a Multiple Myeloma Program in SSA (Chite)

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course

All those interested in registering for this course, please register your information on www.elearning.intercancer.com  if you have any questions or queries please send an email to education@intercancer.com or director@intercancer.com

For more information visit our website www.intercancer.com

International Cancer Institute (ICI) ©2022

Your Partner in Cancer Control in SSA